# Velcade in MALT Lymphoma Patients

> **NCT00373906** · PHASE2 · COMPLETED · sponsor: **Medical University of Vienna** · enrollment: 16 (estimated)

## Conditions studied

- MALT Lymphoma

## Interventions

- **DRUG:** Bortezomib (Velcade)

## Key facts

- **NCT ID:** NCT00373906
- **Lead sponsor:** Medical University of Vienna
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2013-11-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00373906

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00373906, "Velcade in MALT Lymphoma Patients". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00373906. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*